Study Medications
Overencapsulated, double-blind medication was ingested orally by participants twice daily during study weeks 2 to 30. Participants received double-blinded placebo (microcrystalline cellulose) until they met criteria for the RP or AI incentive schedules, at which time they were randomized to bupropion SR (40 participants) or placebo (40 participants). Participants assigned to bupropion SR were titrated from 150 mg to 300 mg over a 3-day period and maintained on 300 mg thereafter. Medication was dispensed weekly in blister packs.